Related by context. All words. (Click for frequent words.) 84 confidence interval CI 78 % CI #.#-#.# [006] 76 % CI #.#-#.# [002] 74 confidence interval #.#-#.# 72 p = .# [002] 72 % CI #.#-#.# [003] 72 CI #.#-#.# [002] 72 % CI #.#-#.# [008] 72 P = .# 71 % CI #.#-#.# [007] 71 p = 70 AOR = 69 CI -#.# 68 % Confidence Interval 68 % CI #.#-#.# [001] 67 df = 66 interquartile range 65 sd = 65 % CI #.#-#.# [004] 65 p = #.# [004] 65 p = #.# [002] 64 CI #.#-#.# [001] 64 n = 64 r = 64 placebo p = 64 P ≤ 64 confidence intervals CIs 63 multivariable adjusted 63 β = 62 nonobese 62 highest tertile 62 mIU L 62 x ULN 61 aOR 61 comorbid 61 MetS 60 -#.# ± [002] 60 g dl 60 univariate analysis 60 p = NS 60 psychiatric comorbidities 60 lowest tertile 60 statistically significant p = 60 CI #.#-#.# p = 60 nonsignificant difference 60 logistic regression analysis 60 mild renal impairment 60 odds ratios ORs 60 pg ml 60 creatinine ratio 60 pg mL 60 MADRS score 59 IQR 59 ng mL 59 postintervention 59 recurrent VTE 59 TAXUS p value 59 leukopenia 59 ß = 59 p = #.# [003] 59 mmol L 59 = #.#-#.# 59 alanine aminotransferase 59 advanced adenoma 59 pmol L 59 ± 59 recurrent venous thromboembolism 59 p ≤ 58 HbA 1c levels 58 nonfatal MI 58 advanced adenomas 58 % CI #.#-#.# [005] 58 comorbidity 58 parous women 58 Hazard Ratio HR 58 advanced neoplasia 58 μmol L 58 MBq 58 univariate analyzes 58 preoperative 58 nonexposed 58 TT genotype 58 sociodemographic characteristics 58 â ‰ ¥ 58 mmol l 58 posttreatment 58 IQR = 58 pmol liter 58 neurodevelopmental impairment 58 lopinavir r arm 58 ug dose 58 p = .# [001] 58 logistic regression model 58 MACCE 58 suicide attempters 58 arterial thromboembolic events 57 comorbid anxiety 57 nmol liter 57 nmol L 57 mIU ml 57 hypophosphatemia 57 MMSE score 57 aged ≥ 57 NNT = 57 suicidal ideation 57 placebo p 57 atopic asthma 57 CC genotype 57 recurrent UTI 57 SGPT 57 comorbid depression 57 mg p = 57 severe neutropenia 57 achieved ACR# 57 ≥ 57 endometrial thickness 57 hip BMD 57 multivariate adjustment 57 adjunctive placebo 57 pT3 57 Brief Psychiatric 57 biochemical recurrence 57 Suicidal ideation 57 ng ml 57 seropositivity 57 mcg QD 57 DAS# [002] 57 nonsignificant 57 TEAEs 57 elevated ALT 57 baseline HbA1c 57 PSA nadir 57 tirofiban 57 postoperative AF 57 multivariate analysis 56 ALT elevation 56 mL/min/#.# m 2 56 depressive symptomatology 56 overt nephropathy 56 MMSE scores 56 statistical significance p 56 FluCAM arm 56 intima media thickness 56 HRQoL 56 colorectal adenoma 56 #.#-#.# p = 56 oxycodone CR 56 kappa = 56 psychiatric morbidity 56 comorbidities 56 definite stent thrombosis 56 mg kg Hematide 56 FOLFIRI alone 56 mmHg diastolic 56 -#.# mg dL [002] 56 g dL 56 #q# deletion syndrome 56 preintervention 56 polyp recurrence 56 mU liter 56 affective psychosis 56 mild renal insufficiency 56 dysuria 56 adjunctive ABILIFY 56 invasive carcinomas 56 hours postdose 56 Exclusion criteria 56 highest quintile 56 hypogonadal 56 infliximab monotherapy 56 tipranavir r 56 serum estradiol 56 covariates 56 preoperative PSA 56 sociodemographic factors 55 atopic 55 febrile neutropenia 55 adenomatous polyps 55 biochemical relapse 55 REYATAZ r arm 55 umol L 55 log# copies mL 55 ± SD 55 multivariable analysis 55 pretest probability 55 NMIBC 55 CrCl 55 multivariate analyzes 55 rs# [004] 55 nonobese patients 55 mcg kg REBETOL 55 mean baseline HbA1c 55 receiving ISENTRESS 55 #mg BID [001] 55 amoxicillin clavulanate 55 multivariate adjusted 55 -#.# mg dL [001] 55 #mg/day [001] 55 headache abdominal pain 55 comparator arm 55 mmHg p = 55 detrusor overactivity 55 serum ALT 55 statistically significant p 55 postoperative complication 55 WOMAC pain 55 hematuria 55 carotid IMT 55 r2 = 55 mg + GLY 55 severe exacerbations 55 nadroparin 55 perioperative complications 55 dyspareunia 55 histologically confirmed 55 affective psychoses 55 Breslow thickness 55 CIN3 55 nasopharyngitis 55 underwent resection 55 interquartile range IQR 55 URTI 55 asthenia 55 CIN2 + 55 tertile 55 rheumatoid factor 55 μg mL 55 BMI z 55 lymph node metastasis 55 autonomic dysfunction 55 XIENCE V vs. 55 HIV uninfected 55 deep venous thromboses 55 multivariate Cox 55 CR CRu 55 extracapsular extension 55 univariate 55 periprocedural 55 ‰ ¥ 55 Postoperatively 55 PREZISTA r arm 55 ECOG PS 55 mmHg systolic 55 median PFS 55 Operative mortality 55 chlamydial infection 55 recurrent atrial fibrillation 55 nmol 55 GH deficiency 55 methotrexate monotherapy 55 μg L 54 ng dL 54 HBeAg negative patients 54 Complication rates 54 quetiapine risperidone 54 nonpsychiatric 54 μg dL 54 syndromal 54 noncardiac 54 BMI ≥ 54 Hazard Ratio = 54 annualized relapse 54 adenotonsillectomy 54 LV dysfunction 54 stent binary restenosis 54 SLNB 54 HCV antibody 54 Depressive symptoms 54 Score TOS 54 enamel defects 54 rebleeding 54 cervicitis 54 #.#/#.# mmHg [001] 54 lispro 54 nondiabetic patients 54 habitual snoring 54 posttransplant 54 HF hospitalization 54 kg m² 54 thyrotropin levels 54 locoregional recurrence 54 RLAI 54 Rating Scale BPRS 54 systolic BP 54 asthma exacerbation 54 -#.# p = 54 interrater reliability 54 Baseline characteristics 54 intraobserver 54 urine albumin 54 liver histology 54 ipsilateral stroke 54 thromboembolism 54 serum concentrations 54 CVD mortality 54 leucopenia 54 kcal d 54 laboratory abnormalities 54 COHb 54 mU L 54 nondepressed 54 de novo AML 54 stage IIIb IV 54 baseline CD4 54 Pneumocystis carinii pneumonia 54 elevated transaminases 54 nondiabetic 54 poststroke 54 ALT flares 54 pooled comparator 54 erythrocyte sedimentation rate 54 COPD exacerbation 54 subscales 54 CR nPR 54 comorbid disorders 54 schizophrenia schizoaffective disorder 54 diabetes mellitus DM 54 tertiles 54 pCR 54 Kaplan Meier analysis 54 Index CDAI 54 Montgomery Åsberg Depression 54 Apgar scores 54 reinfarction 54 binary restenosis 54 seminal vesicle invasion 54 preoperatively 54 diastolic BP 54 mcg linaclotide 54 diastolic hypertension 54 alanine aminotransferase ALT 54 euthymic patients 54 -#.# log# copies mL 54 HBeAg negative 54 mucosal inflammation 54 pT2 54 SUVmax 54 renal insufficiency 54 suicide ideation 54 progesterone receptor negative 54 nonvertebral fracture 54 normotensive 54 comorbid conditions 54 coinfected patients 54 comorbid illnesses 54 virological failure 54 mg kg dose 54 adnexal mass 54 comorbid substance 54 ropivacaine 54 Univariate analysis 54 EDSS scores 54 psychiatric comorbidity 54 microg 53 comorbid psychiatric 53 5-FU/LV 53 achieved statistical significance 53 See WARNINGS 53 nonobstructive 53 QTcF 53 PCa 53 extensive metabolizers 53 hypercalciuria 53 HbA 1c 53 HGPIN 53 Hazard Ratio 53 Hb A1c 53 recurrent DVT 53 fractional anisotropy 53 carotid plaques 53 Injury Severity Score 53 fluticasone salmeterol 53 testicular tumors 53 seronegative 53 vertebral fracture 53 apnea hypopnea index 53 INVEGA ® 53 tolterodine ER 53 airway responsiveness 53 rs# [003] 53 prevalences 53 multivariable analyzes 53 #.#ng/ml 53 lymphocytosis 53 fatigue asthenia 53 4mg/kg 53 postop 53 intravesical therapy 53 mcg mL 53 acute cholecystitis 53 clinically evaluable patients 53 Secondary endpoints included 53 mean baseline A1C 53 #.# df = 53 SGRQ 53 moderately emetogenic 53 extrapyramidal symptoms 53 attending antenatal clinics 53 oral allopurinol 53 generalized tonic clonic seizures 53 elevated IOP 53 hepatorenal syndrome 53 dalteparin 53 experienced virologic failure 53 neoplasias 53 venlafaxine XR 53 neurologic complications 53 radical prostatectomy RP 53 creatinine clearance 53 multiple logistic regression 53 EQ 5D 53 histologic subtype 53 nodal metastases 53 proband 53 Preoperatively 53 tumor histology 53 psychiatric outpatients 53 lifetime abstainers 53 convulsive disorders 53 primary aldosteronism 53 conjunctival hyperemia 53 imipenem 53 PaO 2 53 Main Outcome Measures 53 nonfatal myocardial infarction 53 abnormal cytology 53 thromboembolic 53 euthyroid 53 hypokalemia 53 kg/m2 53 glycated hemoglobin HbA1c 53 linaclotide treated 53 mg d 53 discontinuations due 53 ARCOXIA 53 generalized edema 53 Multivariate analysis revealed 53 moderate renal impairment 53 limiting generalizability 53 KRAS mutations occur 53 subtrochanteric 53 postdischarge 53 progression TTP 53 mm Hg diastolic 53 micafungin 53 ug kg 53 genotype 1b 53 allergic eczema 53 #mg QD [001] 53 BCG vaccinated 53 elevated depressive symptoms 53 PROCTOCORT ® Suppository Hydrocortisone 53 colorectal adenomas 53 left ventricular systolic 53 genotypic resistance 53 ANOVA 53 androgen suppression 53 stomatitis 53 incidence ≥ 53 gastroduodenal 53 mL/min/#.# m2 53 IIIa inhibitors 53 external genital lesions 53 #mg BID [003] 53 postoperative morbidity 53 intact parathyroid hormone 53 spinal cord compression 53 logMAR 53 carotid intima media 53 postprocedure 53 VLBW 53 Subgroup analyzes 53 System IPSS 53 ASCUS 53 lumbar spine BMD 53 antiphospholipid antibodies 53 mcg BID 53 NIH CPSI 53 osteopenic 53 racemic albuterol 53 nonfasting triglyceride levels 53 diameter stenosis 53 PANSS scores 52 SSRI SNRI 52 PREMPRO 52 LVSD 52 cGy 52 fibroids endometriosis 52 -#.# ± [001] 52 hematologic toxicity 52 baseline serum creatinine 52 cerebrovascular accident 52 Visual Analogue Scale VAS 52 nmol l 52 prospectively evaluated 52 Partial Response 52 titrated glipizide 52 PRADAXA #mg 52 affective disorders 52 HBeAg 52 Non inferiority 52 Ishak fibrosis score 52 headache nasopharyngitis 52 rho = 52 EDSS score 52 octreotide LAR 52 Helicobacter pylori eradication 52 Logistic regression 52 treated nonoperatively 52 cervical intraepithelial neoplasia 52 aldosterone antagonist 52 arterial oxygen saturation 52 ATV RTV 52 subclinical hyperthyroidism 52 prostate cancer CaP 52 PLX STROKE targeting 52 flutamide 52 premorbid 52 prolactin elevation 52 coronary stenosis 52 comorbid psychiatric disorders 52 aspartate aminotransferase 52 depression suicidal ideation 52 histological subtype 52 adefovir treated 52 leiomyomas 52 HER2 expression 52 atrophic gastritis 52 specific antigen PSA 52 cerebral oxygenation 52 paresthesias 52 plus aztreonam 52 β blocker 52 morphometric vertebral fractures 52 amenorrhoea 52 Expanded Disability Status 52 Stent thrombosis 52 colorectal neoplasia 52 nonpsychotic 52 HbA1C levels 52 estimated glomerular filtration 52 serum urate levels 52 arthralgia 52 antibody titer 52 coronary artery calcification 52 shorter telomere length 52 #.#mmHg 52 sociodemographic variables 52 plasma uric acid 52 statistically significant predictor 52 μg d 52 distant metastasis 52 lymphovascular invasion 52 neutropenic fever 52 ATACAND 52 bronchioloalveolar carcinoma 52 recurrent acute pancreatitis 52 adenoma recurrence 52 #mmHg [002] 52 concomitant medications 52 carotid stenosis 52 LVEF 52 ertapenem 52 ng dl 52 microbiologically evaluable 52 ≤ 52 HOMA IR 52 IM progesterone 52 clodronate 52 Flu Cy 52 nonfatal stroke 52 -#.# mm Hg 52 plasma creatinine 52 asymptomatic PAD 52 vesicoureteral reflux 52 rhinoconjunctivitis 52 reintubation 52 AST ALT 52 heparin induced thrombocytopenia 52 thromboembolic events 52 mEq L 52 nonmetastatic 52 radiotherapy RT 52 PCWP 52 HRCT 52 β blockers 52 sensory neuropathy 52 Multivariate analyzes 52 epithelial ovarian cancer 52 perioperatively 52 pyrexia 52 extrapyramidal disorder 52 SRBD 52 serum magnesium 52 renal scarring 52 Xalatan R 52 fasting insulin 52 Rating Scale MADRS 52 nonalcoholic steatohepatitis NASH 52 FOLFOX4 52 hypoxemia 52 QRS duration 52 macroalbuminuria 52 echocardiographic parameters 52 tPSA 52 MIC# [001] 52 obstructive coronary artery 52 idiopathic PAH 52 plus OBT 52 hypertension diabetes mellitus 52 microalbuminuria 52 serum IGF 52 log# IU mL 52 AUCs 52 proximal DVT 52 colorectal carcinoma 52 mL kg 52 antenatal depression 52 atopy 52 p = ns 52 urate lowering therapy 52 Y BOCS 52 lymphadenectomy 52 polytherapy 52 FEV ^ sub 52 GnRH agonist 52 Secondary endpoints include 52 oxygen desaturation 52 Comorbid 52 lowest quintile 52 biopsy Gleason 52 venous thromboembolic disease 52 hypercholesterolaemia 52 sensory gating 52 lower extremity amputation 52 aminotransferase elevations greater 52 XIENCE V PROMUS Stent 52 syndromic 52 microbiological eradication 52 -#.# log# 52 ischemia driven 52 attain statistical significance 52 μg g 52 hyperphenylalaninemia HPA due 52 neutrophil counts 52 femoral neck fracture 52 transaminase elevations 52 clinically meaningful improvement 52 ADCS CGIC 52 CCyR 52 min -1 52 chlorambucil 52 severe hypoglycemic 52 CYP#D# inhibitor 52 mGy 52 systolic blood pressures 51 fasting triglyceride levels 51 postinjury 51 cerebrovascular accidents 51 nasopharyngitis headache 51 baseline FEV 51 log# reduction 51 mg QD 51 isolated systolic hypertension 51 serum GGT 51 onset diabetes mellitus 51 EBRT 51 perimenopausal women 51 postoperative complications 51 thyroid carcinoma 51 APTIVUS r 51 symptom severity 51 HIV seronegative 51 Asymptomatic 51 mmol liter 51 T1c 51 highly emetogenic 51 abacavir lamivudine 51 LV ejection fraction 51 plus medroxyprogesterone acetate 51 clinico pathological 51 folic acid takers 51 genital ulcer 51 mg Androxal 51 severe obstructive sleep 51 Erythropoietic therapies may 51 DAS# CRP 51 μg liter 51 multivariable Cox 51 clinicopathological 51 #.#mmol L [001] 51 #OHD 51 perianal 51 hsCRP levels 51 HIV HCV coinfected 51 ß blockers 51 #.#mmol L [002] 51 symptomatic intracerebral hemorrhage 51 NATRECOR R 51 subscale scores 51 mg TID 51 parasitaemia 51 thromboprophylaxis 51 GG genotype 51 μg ml 51 LUTS 51 ultrasonographic 51 IPAH 51 ug ml 51 antiandrogen 51 bivariate analyzes 51 Cream USP 1 51 plasma folate 51 NSTEMI 51 Hb A1C 51 pericardial effusion 51 lopinavir r 51 cirrhotic 51 PREZISTA r 51 systolic dysfunction 51 penile vaginal intercourse 51 ejaculatory dysfunction 51 albumin excretion 51 Acetate Rectal Suppositories 51 coronary calcification 51 QIDS SR 51 normal birthweight 51 anemia hemoglobin 51 hyperlipidaemia 51 hemodynamically significant 51 Â ± 51 achieved sustained virological 51 pentoxifylline 51 oropharyngeal 51 urolithiasis 51 NIHSS score 51 baseline LDH 51 T2DM 51 perioperative mortality 51 virologic failure 51 atypical hyperplasia 51 spontaneous bacterial peritonitis 51 lactate dehydrogenase 51 Prostate specific antigen 51 BUPHENYL R sodium phenylbutyrate 51 psychosocial functioning 51 monoclonal gammopathy 51 antiretroviral naïve 51 leukocyte count 51 locoregional 51 sirolimus stent 51 IPSS 51 squamous histology 51 dysphoric 51 μg kg 51 microscopic colitis 51 BMS p = 51 orchitis 51 HNSCC 51 methacholine challenge 51 tHcy 51 ecchymosis 51 cirrhotic patients 51 nmol L. 51 nonpregnant women 51 atheroma volume 51 ventricular tachyarrhythmia 51 logistic regression 51 clinicopathological features 51 Comorbidities 51 TURBT 51 HADS 51 probands 51 interobserver reliability 51 Postoperative 51 FDA defined valvulopathy 51 logistic regression analyzes 51 dysthymia 51 corticosteroid dose 51 relapsed MM 51 Multivariate analysis 51 tipranavir ritonavir 51 DAS# scores 51 plus octreotide LAR 51 Symptom severity 51 Psoriasis Area 51 GERD symptom 51 antiretroviral naive 51 seroprotection 51 uM 51 atherothrombotic 51 NNRTI resistance 51 ANCOVA 51 thrombophilia 51 Incontinence Impact Questionnaire 51 pyelonephritis 51 euthymic 51 anastomotic leak 51 mL sec 51 serum aminotransferase levels 51 neutrophil count 51 subsyndromal 51 tapentadol ER 51 chemoradiation therapy 51 atypical ductal hyperplasia 51 interval #.#-#.# 51 nodal metastasis 51 thiopurine 51 Scale EDSS score 51 Mean Symptom Complex 51 #ng/ml 51 SCr 51 spontaneous vaginal 51 thyroglobulin 51 undergone radical prostatectomy 51 mcg dL 51 baseline Hb 51 heterozygotes 51 depressive symptoms 51 undergoing liver transplantation 51 Free Survival PFS 51 regression coefficient 51 AUC0 51 symptom exacerbation 51 sUA 51 budesonide pMDI 51 intratympanic 51 hormone receptor negative 51 #.#/# [005] 51 fetal chromosomal 51 distal colon 51 mg tid 51 ipsilateral 51 nulliparous women 51 HBeAg seroconversion 51 Adjuvant chemotherapy 51 isoproterenol 51 ischemic lesions 51 PREZISTA ritonavir 51 breast carcinoma 51 PSQI 51 haematologic 51 nephrolithiasis 51 mg BID dose 51 colonic polyps 51 colorectal neoplasms 51 Primary endpoints 51 subclinical atherosclerosis 51 TDF FTC 51 hematopoietic cancers 51 femoral neck BMD 51 cisplatin vinorelbine 51 chorioamnionitis 51 logistic regression models 50 tamsulosin 50 inhospital mortality 50 HES CEL 50 piperacillin tazobactam 50 Prognostic significance 50 CANCIDAS 50 caspofungin 50 CARDIA 50 ipsilateral breast 50 hydronephrosis 50 voriconazole 50 mg dL 50 inversely associated 50 norethindrone 50 prolonged QT interval 50 dyspnoea 50 abdominal pain abdominal discomfort 50 covariate 50 psychiatric inpatients 50 serum TSH 50 pegylated interferon alfa 2b 50 cilostazol 50 Mg Uk 50 abnormal lipid 50 baseline A1C 50 STRATEGY FOR AN OPEN 50 Postoperative complications 50 refractory ischemia 50 serum potassium 50 pretransplant 50 placebo fluoxetine 50 SDQ 50 HRQOL 50 vaginal hysterectomy 50 placebo dexamethasone 50 Kaplan Meier estimates 50 methacholine 50 thickness IMT 50 hypomagnesemia 50 hepatic enzyme 50 ml kg 50 distant metastases 50 squamous cell histology 50 Neuropsychiatric Inventory NPI 50 familial aggregation 50 coinfection 50 non splenectomized 50 chronic periodontitis 50 arterial thickening 50 schizophreniform disorder 50 endoscopic ultrasonography 50 mg BID 50 atazanavir ritonavir 50 solifenacin 50 endometrial carcinoma 50 postmenopausal osteoporotic women 50 nonadherence 50 K ras mutations 50 salmeterol fluticasone propionate 50 neurocognitive functioning 50 International Prostate Symptom 50 cerebrovascular events 50 certolizumab 50 pheochromocytoma 50 diabetes hypertension hyperlipidemia 50 sensitivity specificity 50 seroconverted 50 hypoglycemic events 50 diastolic blood pressures 50 systemic corticosteroid 50 elevated serum creatinine 50 elevated troponin 50 virologic response 50 ziprasidone 50 symptomatic VTE 50 chi ^ sup 50 aminotransferase levels 50 PSADT 50 cTnI 50 grade squamous intraepithelial 50 CORE OM 50 underwent surgical resection 50 chlorthalidone 50 median CD4 50 rs# [002] 50 VTEs 50 nonsevere 50 abdominal adiposity 50 mechanically ventilated patients 50 coronary revascularization 50 nontraumatic 50 protein excretion 50 HAM D# 50 prostatic adenocarcinoma 50 nonvertebral fractures 50 receiving INTRON 50 somatoform disorders 50 mm Hg 50 nicotine metabolite 50 recurrent wheezing 50 extracolonic findings 50 dysfunctional voiding 50 dapagliflozin plus 50 #.#mg/dL 50 CIN3 + 50 neurologic abnormalities 50 #.#-#.# [005] 50 UGT#A# * 50 distal colon cancer 50 cells mcL 50 subclinical hypothyroidism 50 dyspnea 50 mg/# hours 50 achieved PASI 50 elevated CRP 50 mcg kg 50 CIMZIA TM certolizumab pegol 50 myocardial infarction MI 50 BRCA1 mutation carriers 50 Lumbar spine 50 mcg albinterferon alfa 2b 50 esophageal carcinoma 50 paroxysmal AF 50 Main Outcome Measure 50 thrombocytopenic 50 plus GP IIb 50 mg estradiol 50 systolic hypertension 50 IIIa inhibitor 50 rFSH 50 Fasting blood glucose 50 corrected QT interval 50 aspartate aminotransferase AST 50 retropubic 50 peripheral edema 50 undergoing radical cystectomy 50 dysglycemia 50 parkinsonism 50 F FDG PET 50 hypoactive 50 elevated LDH 50 nicardipine 50 normothermic 50 ACR Pedi 50 transferrin saturation